Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sun Yat-sen University
National Cancer Institute (NCI)
Big Ten Cancer Research Consortium
Beth Israel Deaconess Medical Center
Mayo Clinic
NRG Oncology
Lumos Pharma
Actuate Therapeutics Inc.
UNC Lineberger Comprehensive Cancer Center
Arcus Biosciences, Inc.
Bristol-Myers Squibb
iOnctura
Washington University School of Medicine
SWOG Cancer Research Network
AstraZeneca
Eastern Cooperative Oncology Group
Hoosier Cancer Research Network
EBG MedAustron GmbH
Innovent Biologics (Suzhou) Co. Ltd.
City of Hope Medical Center
Pfizer
Ipsen
Medical College of Wisconsin
Akeso
Pfizer
Lokon Pharma AB
UNC Lineberger Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
City of Hope Medical Center
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Sun Yat-sen University
Emory University
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Queen Mary University of London
Alliance for Clinical Trials in Oncology
Mayo Clinic
Suzhou Transcenta Therapeutics Co., Ltd.
Emory University
Mayo Clinic
Oncolytics Biotech
University Health Network, Toronto
M.D. Anderson Cancer Center
Shanghai Zhongshan Hospital
Massachusetts General Hospital